Cyfuse Biomedical

What Cyfuse Biomedical does

Cyfuse Biomedical K.K. is a Japanese clinical-stage biotechnology company that develops and commercializes scaffold-free 3D bioprinting systems and cell-based products for regenerative medicine and drug discovery. Founded in 2010 and headquartered in Tokyo with an additional Fukuoka office, the company went public on the Tokyo Stock Exchange Growth Market in December 2022 (ticker: 4892) and added a secondary listing on the Fukuoka Stock Exchange Q-Board in December 2025. The company operates with 11–50 employees and an enterprise-focused go-to-market combining direct sales with channel partnerships.

The company's core technology is the proprietary Kenzan Method, a scaffold-free bioprinting approach in which cell spheroids are fixed on a needle array and stacked into three-dimensional tissues without scaffolds or exogenous materials. This platform underpins the S-PIKE bio-3D printer (the flagship hardware product), the Human 3D Mini Liver drug discovery evaluation tool (with a Disease Model line launched in December 2025), the newly developed 3D Mini Intestine Model (announced November 2025), and a pipeline of 3D Cell Products—including cell-made artificial blood vessels and 3D nerve conduits—currently in clinical trials at Saga University and Kyoto University. The Kenzan Method and S-PIKE are registered trademarks; supporting patents and clinical regulatory pathways create a defensible position in a niche field.

Cyfuse generates revenue through three streams: hardware sales of the S-PIKE bio-3D printer (distributed in Japan by Sysmex Corporation and globally by Marubeni Corporation), product sales of drug discovery tools including the Human 3D Mini Liver family, and pre-commercial regenerative medicine products expected to reach commercialization via licensing/royalty economics. The customer base is concentrated in pharmaceutical and biotech companies (for drug discovery tools), hospitals and academic medical centers (for clinical-stage regenerative medicine products), and research institutions. The company has built a deep partnership ecosystem with major Japanese corporates—Taiyo Holdings (manufacturing), Hitachi Global Life Solutions (modular CPC), Iwatani, Fujimori/Zacros, NSK, Medipal Holdings, Kuraray, and PHC Corporation—covering manufacturing scale-up, automation, materials, and distribution. Pricing is quote-based and not publicly disclosed.

Name

Cyfuse Biomedical

Legal name

株式会社サイフューズ

Website

https://cyfusebio.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Cyfuse Biomedical is a Tokyo-based clinical-stage Japanese biotech that develops scaffold-free 3D bioprinting systems and cell-based products for regenerative medicine and drug discovery, serving pharmaceutical companies, hospitals, and research institutions via its proprietary Kenzan Method platform.

Ownership category

akta.pro rank

Product category

3D Bioprinting and Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

3D Bioprinting & Biofabrication (HLAAAGAC)

akta.pro secondary industries

Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)

Keywords

• 3D bioprinting systems
• Regenerative medicine products
• Spheroid-based tissue engineering
• Drug discovery tools
• Cell-based therapeutics

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Bio-3D Printer Sales: Sale of S-PIKE bio-3D printer systems to research institutions, pharmaceutical companies, and healthcare facilities
2. Drug Discovery Support Tools: Sales of Human 3D Mini-Liver products and services for pharmaceutical drug discovery and toxicity evaluation
3. Regenerative Medicine Products: Development and potential commercialization of 3D cell products for regenerative medicine applications including artificial blood vessels and nerve conduits

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Cyfuse Biomedical develops scaffold-free 3D bioprinting systems using its proprietary Kenzan Method to construct three-dimensional tissues from cell spheroids without scaffolds. Its core commercial offerings are the S-PIKE bio-3D printer (hardware), drug discovery support tools such as the Human 3D Mini Liver, and a pipeline of 3D cell products (artificial blood vessels, nerve conduits) for regenerative medicine applications.

Product overview

Cyfuse Biomedical operates as a bio 3D printing platform company offering both hardware and biological products. The core offering consists of the S-PIKE® bio 3D printer, which uses a unique needle-array system to stack cell spheroids into three-dimensional tissues without scaffold materials. Complementing the hardware are biological products including the Human 3D Mini Liver (a drug discovery evaluation tool) and a pipeline of 3D Cell Products (100% cell-derived tissues and organs such as artificial blood vessels and nerve conduits) targeting regenerative medicine applications. A new compact dispensing machine (CAP) was launched in 2026. The portfolio is unified by the company's scaffold-free spheroid-based bioprinting platform technology, which serves both the drug discovery tools segment and the regenerative medicine products segment.

Differentiator

Problem solved

Functional benefit

Brands

• Cyfuse: Company brand name used internationally; Japanese name is 株式会社サイフューズ (Cyfuse Biomedical K.K.)

Products and services

• S-PIKE® (スパイク) Bio 3D Printing System Flagship bio-3D printer that arrays and fixes spheroids on a single needle and aligns those needles to construct three-dimensional tissues and organs. Sold to pharmaceutical companies, research institutions, and healthcare facilities for regenerative medicine and drug discovery research.
• Human 3D Mini Liver (ヒト3Dミニ肝臓) A scaffold-free 3D bio-printed human liver tissue that reproduces human liver function as an innovative in vitro evaluation model. Used by pharmaceutical companies for drug toxicity screening, metabolic function assessment, and disease-specific modeling.
• 3D Cell Products (3D細胞製品) Tissues and organs manufactured from 100% cells using the company's bio-3D printing platform. Includes cell-based artificial blood vessels, three-dimensional nerve conduits, and other regenerative medicine products intended for clinical applications in hospitals and medical institutions.
• 3D Mini Intestine Model (3Dミニ腸管モデル) A 3D mini intestine model expanding Cyfuse's organoid and tissue model portfolio for pharmaceutical drug discovery and preclinical evaluation applications.
• CAP (折りたたみ式コンパクト型分注機) - Folding Compact Dispensing Machine A folding compact dispensing machine used for precision liquid handling in cell and tissue preparation workflows supporting bioprinting operations.

Quantifiable outcome

• World's first clinical trial for cell-made artificial blood vessels using patient's own cells
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered major, regional and core.

• NSK Ltd. (Nippon Seiki)majorStrategic or Co-development Partner · 17 March 2026Joint development of new bio-3D printer for commercial production of regenerative medicine and 3D cell products.
• Kuraray Co., Ltd.majorStrategic or Co-development Partner · 1 December 2025Basic agreement for business and capital partnership in regenerative medicine and cell therapy field.
• PHC CorporationmajorTechnology or Integration · 1 March 2025PHC Corporation and Cyfuse Biomedical announced advanced production technology for regenerative and cell therapy applications in March 2025
• NSK Ltd. (Nippon Seiki)majorStrategic or Co-development Partner · 23 December 2022Collaboration for new technology development in regenerative and cell therapy field. Joint development for factory automation, system integration, and digital transformation for next-generation manufacturing.
• Fukuoka Jisho CorporationregionalStrategic or Co-development Partner · 25 March 2022Business and capital partnership for regional revitalization through biotech medical community in Kyushu/Fukuoka area.
• Medipal Holdings CorporationmajorStrategic or Co-development Partner · 24 December 2021Development investment agreement for practical application of regenerative medicine products. Medipal provides distribution network and pharmaceutical logistics expertise.
• Fujimori Corporation (Zacros)majorStrategic or Co-development Partner · 29 January 2021Business and capital partnership for regenerative and cell therapy field. Joint technology development for mass cell culture technology and cell product commercialization.
• Hitachi Global Life Solutions, Inc.majorStrategic or Co-development Partner · 27 July 2020Co-developed next-generation module type Cell Processing Center (CPC) for manufacturing cell products. Partnership for establishing new manufacturing equipment models.
• Iwatani CorporationmajorStrategic or Co-development Partner · 7 July 2020Business and capital partnership for practical application of 3D cell products. Iwatani provides infrastructure supplier expertise for commercialization.
• Marubeni CorporationcoreChannel Partner/ Reseller/ Distributor · 15 October 2019Global expansion partnership for S-PIKE bio-3D printer worldwide distribution. Marubeni supports international sales and market development.
• Taiyo Holdings Co., Ltd.coreStrategic or Co-development Partner · 15 February 2019Comprehensive partnership for accelerating product manufacturing in regenerative and cell therapy field. Taiyo Pharmatech operates manufacturing facility with next-generation module CPC developed with Hitachi Global Life Solutions.
• Sysmex CorporationcoreChannel Partner/ Reseller/ Distributor · 29 January 2019Sales partnership for S-PIKE bio-3D printer distribution in Japan market. Sysmex serves as primary sales partner for the bio-3D printer products.
• Sekisui Chemical Co., Ltd.majorStrategic or Co-development Partner · 13 September 2018Business partnership for expanding drug discovery support services. Collaboration with Sekisui Medical for practical application of 3D structures for drug discovery.

Scale indicators4 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• CELLINK (BICO Group): Global leader in 3D bioprinting hardware, bioinks, and lab automation. Directly competes with Cyfuse's S-PIKE printer platform and offers comparable scaffold-based bioprinting consumables to research and pharma customers worldwide.
• Organovo: US-based pioneer in 3D bioprinted human tissues, with focus on liver and intestinal tissue models for drug discovery and disease modeling. Comparable in product category (3D tissue products for pharma R&D) though scaffold-based rather than scaffold-free.
• Aspect Biosystems: Canada-based bioprinting company developing tissue therapeutics using proprietary microfluidic 3D bioprinting platform. Directly comparable as a tissue-engineering platform targeting regenerative medicine applications with bioprinted tissue products.
• Poietis: France-based 3D bioprinting company with laser-assisted bioprinting technology for tissue engineering and regenerative medicine. Comparable as a bioprinting platform player serving pharma research and cell therapy development.
• InSphero: Switzerland-based 3D cell culture company producing organoid models (liver, islet, tumor) for drug discovery and toxicology. Directly comparable to Cyfuse's 3D Mini Liver drug-discovery tool offering.
• Emulate: US-based organ-on-chip platform company whose liver-chip and intestine-chip compete with Cyfuse's 3D Mini Liver and 3D Mini Intestine for pharma in vitro evaluation budgets.

Broad incumbents

• Fujifilm: Japanese conglomerate with a significant regenerative medicine and cell therapy business (CDMO, iPSC-derived products). An external director of Cyfuse is a former Fujifilm life sciences executive, indicating deep industry overlap.
• 3D Systems: US-based broad 3D printing incumbent with a healthcare/bioprinting division (including the Allevi bioprinter line). Competes broadly in medical and dental 3D printing applications adjacent to Cyfuse's healthcare focus.

Regional players

• Healios K.K. Japanese clinical-stage cell therapy company developing stem cell treatments for regenerative medicine indications. Comparable as a Japan-domiciled regenerative medicine company advancing cell-based therapies through clinical trials.

Emerging players

• Regemat 3D: Spain-based emerging player in 3D bioprinting hardware and bioinks focused on personalized regenerative medicine. Comparable as a niche bioprinting platform targeting clinical and research applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/cyfuse_official
• LinkedInlinkedin.com/company/cyfuse-biomedical-k-k-

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds8 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyfuse Biomedical